%A Bai,Yiyang %A Wang,Xiao %A Hou,Jia %A Geng,Luying %A Liang,Xuan %A Ruan,Zhiping %A Guo,Hui %A Nan,Kejun %A Jiang,Lili %D 2020 %J Frontiers in Genetics %C %F %G English %K malignant pleural mesothelioma,Gene Expression,Signature,overall survival,prognosis %Q %R 10.3389/fgene.2020.00899 %W %L %M %P %7 %8 2020-August-07 %9 Original Research %# %! Five-gene signature for MPM prognosis %* %< %T Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients %U https://www.frontiersin.org/articles/10.3389/fgene.2020.00899 %V 11 %0 JOURNAL ARTICLE %@ 1664-8021 %X Malignant pleural mesothelioma (MPM), predominantly caused by asbestos exposure, is a highly aggressive cancer with poor prognosis. The staging systems currently used in clinics is inadequate in evaluating the prognosis of MPM. In this study, a five-gene signature was developed and enrolled into a prognostic risk score model by LASSO Cox regression analysis based on two expression profiling datasets (GSE2549 and GSE51024) from Gene Expression Omnibus (GEO). The five-gene signature was further validated using the Cancer Genome Atlas (TCGA) MPM dataset. Univariate and multivariate Cox analyses proved that the five-gene signature was an independent prognostic factor for MPM. The signature remained statistically significant upon stratification by Brigham stage, AJCC stage, gender, tumor size, and lymph node status. Time-dependent receiver operating characteristic (ROC) curve indicated good performance of our model in predicting 1- and 2-years overall survival in MPM patients. The C-index was 0.784 for GSE2549 and 0.753 for the TCGA dataset showing moderate predictive accuracy of our model. Furthermore, Gene Set Enrichment Analysis suggested that the five-gene signature was related to pathways resulting in MPM tumor progression. Together, we have established a five-gene signature significantly associated with prognosis in MPM patients. Hence, the five-genes signature may serve as a potentially useful prognostic tool for MPM patients.